# Clinical Feasibility of the BinaxNOW™ COVID-19/Flu A&B Combo in the Southern Hemisphere

> **NCT06928129** · NA · NOT_YET_RECRUITING · sponsor: **Abbott Rapid Dx** · enrollment: 700 (estimated)

## Conditions studied

- Influenza Type A
- Influenza Type B
- COVID-19

## Interventions

- **DIAGNOSTIC_TEST:** BinaxNOW™ COVID-19/Flu A&B Combo Self-Test

## Key facts

- **NCT ID:** NCT06928129
- **Lead sponsor:** Abbott Rapid Dx
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2025-11-01
- **Final completion:** 2025-11-01
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2025-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06928129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06928129, "Clinical Feasibility of the BinaxNOW™ COVID-19/Flu A&B Combo in the Southern Hemisphere". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06928129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*